ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Corporate Overview January 16th

<< Previous

Bullboard Posts

Next >>

Comment by Speyeder999on Jan 19, 2023 1:19pm

195 Views

Post# 35233632

RE:RE:RE:RE:RE:RE:RE:RE:RE:Corporate Overview January 16th

You are correct Farmer, everything you say is hard to dispute. But this info isn't new and we've known it for quite some time. Whether it will it be a buyout, a partnership or a financing that the new CEO was brought on board for, who knows, it remains a risky play, one that I'm willing to see how it plays out.
One thing for sure, it's nearing the "$hit or get off the pot" time.

GLTA

<< Previous

Bullboard Posts

Next >>

The investment impact of the U.S. 25% tariff on Canadian imports